414 related articles for article (PubMed ID: 23373998)
1. Distant metastasis in triple-negative breast cancer.
Tseng LM; Hsu NC; Chen SC; Lu YS; Lin CH; Chang DY; Li H; Lin YC; Chang HK; Chao TC; Ouyang F; Hou MF
Neoplasma; 2013; 60(3):290-4. PubMed ID: 23373998
[TBL] [Abstract][Full Text] [Related]
2. [Treatment outcomes and clinicopathologic characteristics of advanced triple-negative breast cancer patients].
Zhang P; Xu BH; Ma F; Li Q; Yuan P; Wang JY; Zhang P
Zhonghua Zhong Liu Za Zhi; 2011 May; 33(5):381-4. PubMed ID: 21875471
[TBL] [Abstract][Full Text] [Related]
3. Primary and secondary distant metastatic breast cancer: two sides of the same coin.
Güth U; Magaton I; Huang DJ; Fisher R; Schötzau A; Vetter M
Breast; 2014 Feb; 23(1):26-32. PubMed ID: 24215983
[TBL] [Abstract][Full Text] [Related]
4. Optimal surveillance for postoperative metastasis in breast cancer patients.
Makita M; Sakai T; Ogiya A; Kitagawa D; Morizono H; Miyagi Y; Iijima K; Iwase T
Breast Cancer; 2016 Mar; 23(2):286-94. PubMed ID: 25294313
[TBL] [Abstract][Full Text] [Related]
5. Predictive factors for efficacy of capecitabine in heavily pretreated patients with metastatic breast cancer.
Osako T; Ito Y; Ushijima M; Takahashi S; Tokudome N; Sugihara T; Iwase T; Matsuura M; Hatake K
Cancer Chemother Pharmacol; 2009 Apr; 63(5):865-71. PubMed ID: 18670777
[TBL] [Abstract][Full Text] [Related]
6. Organotropism and prognostic marker discordance in distant metastases of breast carcinoma: fact or fiction? A clinicopathologic analysis.
St Romain P; Madan R; Tawfik OW; Damjanov I; Fan F
Hum Pathol; 2012 Mar; 43(3):398-404. PubMed ID: 21840040
[TBL] [Abstract][Full Text] [Related]
7. Disparities in the survival improvement of recurrent breast cancer.
Anan K; Mitsuyama S; Koga K; Tanabe R; Saimura M; Tanabe Y; Watanabe M; Suehara N; Matsunaga H; Nishihara K; Abe Y; Nakano T; Tamae K; Ono M; Toyoshima S
Breast Cancer; 2010; 17(1):48-55. PubMed ID: 19350357
[TBL] [Abstract][Full Text] [Related]
8. Profile and Outcome of Supraclavicular Metastases in Patients with Metastatic Breast Cancer: Discordance of Receptor Status Between Primary and Metastatic Site.
Thangarajah F; Vogel C; Pahmeyer C; Eichler C; Holtschmidt J; Ratiu D; Mallmann P; Malter W
Anticancer Res; 2018 Oct; 38(10):6023-6026. PubMed ID: 30275235
[TBL] [Abstract][Full Text] [Related]
9. Tumor characteristics and recurrence patterns in triple negative breast cancer: a comparison between younger (<65) and elderly (≥65) patients.
Königsberg R; Pfeiler G; Klement T; Hammerschmid N; Brunner A; Zeillinger R; Singer C; Dittrich C
Eur J Cancer; 2012 Nov; 48(16):2962-8. PubMed ID: 22647688
[TBL] [Abstract][Full Text] [Related]
10. Cytoplasmic CXCR4 high-expression exhibits distinct poor clinicopathological characteristics and predicts poor prognosis in triple-negative breast cancer.
Chen HW; Du CW; Wei XL; Khoo US; Zhang GJ
Curr Mol Med; 2013 Mar; 13(3):410-6. PubMed ID: 23331013
[TBL] [Abstract][Full Text] [Related]
11. [Clinical characteristics and survival in the operable breast cancer patients with different molecular subtypes].
Zhang HM; Zhang BN; Xuan LX; Zhao P
Zhonghua Zhong Liu Za Zhi; 2009 Jun; 31(6):447-51. PubMed ID: 19950556
[TBL] [Abstract][Full Text] [Related]
12. Prognostic factors and survival according to tumour subtype in women presenting with breast cancer brain metastases at initial diagnosis.
Leone JP; Leone J; Zwenger AO; Iturbe J; Leone BA; Vallejo CT
Eur J Cancer; 2017 Mar; 74():17-25. PubMed ID: 28335884
[TBL] [Abstract][Full Text] [Related]
13. Retrospective analysis of risk factors for central nervous system metastases in operable breast cancer: effects of biologic subtype and Ki67 overexpression on survival.
Ishihara M; Mukai H; Nagai S; Onozawa M; Nihei K; Shimada T; Wada N
Oncology; 2013; 84(3):135-40. PubMed ID: 23235554
[TBL] [Abstract][Full Text] [Related]
14. Effect of hormone therapy on long-term outcomes of patients with human epidermal growth factor receptor 2- and hormone receptor-positive metastatic breast cancer: real world experience in China.
Du F; Yuan P; Wang JY; Ma F; Fan Y; Luo Y; Xu BH
Asian Pac J Cancer Prev; 2015; 16(3):903-7. PubMed ID: 25735380
[TBL] [Abstract][Full Text] [Related]
15. Clinical features and course of brain metastases in triple-negative breast cancer: comparison with human epidermal growth factor receptor 2-positive and other type at single institution in Korea.
Jang G; Lee SS; Ahn JH; Jung KH; Lee H; Gong G; Kim HH; Ahn SD; Son BH; Ahn SH; Kim SB
Breast Cancer Res Treat; 2011 Jul; 128(1):171-7. PubMed ID: 21519835
[TBL] [Abstract][Full Text] [Related]
16. Impact of triple-negative phenotype on prognosis of patients with breast cancer brain metastases.
Xu Z; Schlesinger D; Toulmin S; Rich T; Sheehan J
Int J Radiat Oncol Biol Phys; 2012 Nov; 84(3):612-8. PubMed ID: 22436795
[TBL] [Abstract][Full Text] [Related]
17. De novo metastasis in breast cancer: occurrence and overall survival stratified by molecular subtype.
Press DJ; Miller ME; Liederbach E; Yao K; Huo D
Clin Exp Metastasis; 2017 Dec; 34(8):457-465. PubMed ID: 29288366
[TBL] [Abstract][Full Text] [Related]
18. Limited overall survival in patients with brain metastases from triple negative breast cancer.
Morris PG; Murphy CG; Mallam D; Accordino M; Patil S; Howard J; Omuro A; Beal K; Seidman AD; Hudis CA; Fornier MN
Breast J; 2012; 18(4):345-50. PubMed ID: 22607041
[TBL] [Abstract][Full Text] [Related]
19. Pattern of metastatic spread in triple-negative breast cancer.
Dent R; Hanna WM; Trudeau M; Rawlinson E; Sun P; Narod SA
Breast Cancer Res Treat; 2009 May; 115(2):423-8. PubMed ID: 18543098
[TBL] [Abstract][Full Text] [Related]
20. Breast cancer: metastatic patterns and their prognosis.
Patanaphan V; Salazar OM; Risco R
South Med J; 1988 Sep; 81(9):1109-12. PubMed ID: 3420442
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]